The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
Jeremy A Falk, Kiran J Philip, Ernst R SchwarzCedars Sinai Women’s Guild Lung Institute, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USAAbstract: Pulmonary hypertension (PH) is found in a vast array of diseases, with a minority representing pulmonary art...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-04-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/the-emergence-of-oral-tadalafil-as-a-once-daily-treatment-for-pulmonar-a4291 |
| _version_ | 1828746732551274496 |
|---|---|
| author | Jeremy A Falk Kiran J Philip Ernst R Schwarz |
| author_facet | Jeremy A Falk Kiran J Philip Ernst R Schwarz |
| author_sort | Jeremy A Falk |
| collection | DOAJ |
| description | Jeremy A Falk, Kiran J Philip, Ernst R SchwarzCedars Sinai Women’s Guild Lung Institute, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USAAbstract: Pulmonary hypertension (PH) is found in a vast array of diseases, with a minority representing pulmonary arterial hypertension (PAH). Idiopathic PAH or PAH in association with other disorders has been associated with poor survival, poor exercise tolerance, progressive symptoms of dyspnea, and decreased quality of life. Left untreated, patients with PAH typically have a progressive decline in function with high morbidity ultimately leading to death. Advances in medical therapy for PAH over the past decade have made significant inroads into improved function, quality of life, and even survival in this patient population. Three classes of pulmonary artery-specific vasodilators are currently available in the United States. They include prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 (PDE5) inhibitors. In May 2009, the FDA approved tadalafil, the first once-daily PDE5 inhibitor for PAH. This review will outline the currently available data on tadalafil and its effects in patients with PAH.Keywords: PDE-5 inhibition, pulmonary hypertension, tadalafil |
| first_indexed | 2024-04-14T04:30:12Z |
| format | Article |
| id | doaj.art-045a417005dc49a68cc5217ff87876de |
| institution | Directory Open Access Journal |
| issn | 1176-6344 1178-2048 |
| language | English |
| last_indexed | 2024-04-14T04:30:12Z |
| publishDate | 2010-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-045a417005dc49a68cc5217ff87876de2022-12-22T02:12:04ZengDove Medical PressVascular Health and Risk Management1176-63441178-20482010-04-012010default273280The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertensionJeremy A FalkKiran J PhilipErnst R SchwarzJeremy A Falk, Kiran J Philip, Ernst R SchwarzCedars Sinai Women’s Guild Lung Institute, Cedars Sinai Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USAAbstract: Pulmonary hypertension (PH) is found in a vast array of diseases, with a minority representing pulmonary arterial hypertension (PAH). Idiopathic PAH or PAH in association with other disorders has been associated with poor survival, poor exercise tolerance, progressive symptoms of dyspnea, and decreased quality of life. Left untreated, patients with PAH typically have a progressive decline in function with high morbidity ultimately leading to death. Advances in medical therapy for PAH over the past decade have made significant inroads into improved function, quality of life, and even survival in this patient population. Three classes of pulmonary artery-specific vasodilators are currently available in the United States. They include prostanoids, endothelin receptor antagonists, and phosphodiesterase type 5 (PDE5) inhibitors. In May 2009, the FDA approved tadalafil, the first once-daily PDE5 inhibitor for PAH. This review will outline the currently available data on tadalafil and its effects in patients with PAH.Keywords: PDE-5 inhibition, pulmonary hypertension, tadalafilhttp://www.dovepress.com/the-emergence-of-oral-tadalafil-as-a-once-daily-treatment-for-pulmonar-a4291 |
| spellingShingle | Jeremy A Falk Kiran J Philip Ernst R Schwarz The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension Vascular Health and Risk Management |
| title | The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension |
| title_full | The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension |
| title_fullStr | The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension |
| title_full_unstemmed | The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension |
| title_short | The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension |
| title_sort | emergence of oral tadalafil as a once daily treatment for pulmonary arterial hypertension |
| url | http://www.dovepress.com/the-emergence-of-oral-tadalafil-as-a-once-daily-treatment-for-pulmonar-a4291 |
| work_keys_str_mv | AT jeremyafalk theemergenceoforaltadalafilasaoncedailytreatmentforpulmonaryarterialhypertension AT kiranjphilip theemergenceoforaltadalafilasaoncedailytreatmentforpulmonaryarterialhypertension AT ernstrschwarz theemergenceoforaltadalafilasaoncedailytreatmentforpulmonaryarterialhypertension AT jeremyafalk emergenceoforaltadalafilasaoncedailytreatmentforpulmonaryarterialhypertension AT kiranjphilip emergenceoforaltadalafilasaoncedailytreatmentforpulmonaryarterialhypertension AT ernstrschwarz emergenceoforaltadalafilasaoncedailytreatmentforpulmonaryarterialhypertension |